Last reviewed · How we verify
BAY80-6964 fixed dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BAY80-6964 fixed dose (BAY80-6964 fixed dose) — Bayer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BAY80-6964 fixed dose TARGET | BAY80-6964 fixed dose | Bayer | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BAY80-6964 fixed dose CI watch — RSS
- BAY80-6964 fixed dose CI watch — Atom
- BAY80-6964 fixed dose CI watch — JSON
- BAY80-6964 fixed dose alone — RSS
Cite this brief
Drug Landscape (2026). BAY80-6964 fixed dose — Competitive Intelligence Brief. https://druglandscape.com/ci/bay80-6964-fixed-dose. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing